Correlation Between Citigroup and OncoCyte Corp

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citigroup and OncoCyte Corp at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and OncoCyte Corp into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and OncoCyte Corp, you can compare the effects of market volatilities on Citigroup and OncoCyte Corp and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of OncoCyte Corp. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and OncoCyte Corp.

Diversification Opportunities for Citigroup and OncoCyte Corp

-0.76
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Citigroup and OncoCyte is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and OncoCyte Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OncoCyte Corp and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with OncoCyte Corp. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OncoCyte Corp has no effect on the direction of Citigroup i.e., Citigroup and OncoCyte Corp go up and down completely randomly.

Pair Corralation between Citigroup and OncoCyte Corp

Taking into account the 90-day investment horizon Citigroup is expected to generate 0.61 times more return on investment than OncoCyte Corp. However, Citigroup is 1.65 times less risky than OncoCyte Corp. It trades about 0.07 of its potential returns per unit of risk. OncoCyte Corp is currently generating about -0.01 per unit of risk. If you would invest  6,079  in Citigroup on September 1, 2024 and sell it today you would earn a total of  1,008  from holding Citigroup or generate 16.58% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Citigroup  vs.  OncoCyte Corp

 Performance 
       Timeline  
Citigroup 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.
OncoCyte Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days OncoCyte Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Citigroup and OncoCyte Corp Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citigroup and OncoCyte Corp

The main advantage of trading using opposite Citigroup and OncoCyte Corp positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, OncoCyte Corp can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OncoCyte Corp will offset losses from the drop in OncoCyte Corp's long position.
The idea behind Citigroup and OncoCyte Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.